The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
about
Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7Where is biological therapy going?Infliximab.Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alphaAntitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Role of osteopontin in amplification and perpetuation of rheumatoid synovitis.Building towards a consensus for the use of tumour necrosis factor blocking agents.The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?A cascade of cytokines mediates mechanical inflammatory hypernociception in mice.Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.Biological agents: a novel approach to the therapy of rheumatoid arthritis.Rheumatoid arthritis and tumor necrosis factor alpha.Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4.Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice.Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent.Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico ExplorationsAnalysing the effect of novel therapies on cytokine expression in experimental arthritis.Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.TNFalpha blockade in human diseases: mechanisms and future directions.Delayed molecular responses to brain irradiation.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Proliferative responses to recall antigens are associated with pregnancy outcome in women with a history of recurrent spontaneous abortion.Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.Pro- and anti-inflammatory cytokines in rheumatoid arthritis.The use of biologics in the treatment of rheumatoid arthritis (RA)--the good news and the bad news.An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis.Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo.Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model.Sexual dimorphism in innate immunity.Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw.Treatment of rheumatoid arthritis in the third millennium.Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis.Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice.Therapeutic antibody fragments with prolonged in vivo half-livesTumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis
P2860
Q24675216-E162A8DC-5F6B-4984-8730-E0DCFE5B4310Q24792345-3357540F-17FE-4E3A-86C3-07439DABC862Q30307998-67910948-C562-4E2A-A500-A3721FF6A695Q33618096-A981218D-E3EF-4D97-88DE-32E04BC9932FQ33641577-01CF1D30-4750-4479-9B41-AC45D15A7AA8Q33700555-B211C29C-0F61-4E1F-9225-8757A0A01EF9Q33782282-64C5A535-5086-4967-97D2-C3099E46CCDEQ33782321-FCEEA54D-57C4-4A42-B021-723AEF171AAEQ33819799-6D3BD826-1D7A-40F0-BCDE-545CF6ADBFC5Q33944344-13137F9B-DA5E-4500-91DF-265D54D0DFD1Q34071292-6C025A77-66E1-41A8-89E1-E650F96BA6D4Q34071308-8E0EABF8-B877-4BDC-95A4-3F54ED5E274BQ34074934-41BEA0A8-EF14-4CF7-A847-C158BCAB5AF6Q34572250-426BC5DA-1BC4-4A7A-8D49-0DFC6FBB642AQ35028324-15533A27-EF08-4AD6-9F83-2BC401A20A77Q35550664-56DF7561-B65F-445C-8BFA-4F80E3459E22Q35554897-959A378F-1E5B-4B59-85F8-B1D150F6D73FQ36172262-6E84BAF3-A8FB-4949-BA05-0655A2A36B0FQ36183900-9CC714D6-1666-4F02-91FE-731A48FF049DQ36271120-3FC578A9-E3B4-4FB2-9762-A3EA6CE562C7Q36364193-7E8CE5C7-1D15-4ECD-9DB6-A37FB22125B2Q36536886-C59A0C3E-C449-4B0F-BEB9-5C099DC1F18AQ36874642-A6663215-6614-4C02-BD55-425BFC8A26B2Q37290665-0822FC26-90C4-4015-994B-93D57EC5F6F6Q37372306-74CEE7A7-0492-44C1-904E-BE61910B3871Q37374541-D156B17A-387B-45CD-A54F-7CC7D42E1175Q40861531-F73ECE94-E802-4149-AEC5-51048A8E49F2Q41465945-D6626C0D-1F5B-4E00-B9A2-26EF7B721693Q41478121-A5A12E65-DCA5-45E1-B6C2-ED2069A71D00Q42453486-E64C6720-B985-4299-B979-F8DC3A323D55Q43854219-895E9A6D-7966-4902-ABA8-5AB6072F9C4CQ43870766-68C5EABD-676C-46CC-A74D-EC03987E0D92Q44060534-4234A094-D11D-407A-ABDD-8D0BC0D8CA82Q45153959-1C95F305-F1B6-4975-B7F6-38FDDA5D003BQ45885240-11EE6714-9A2E-456D-9D2D-EC93F63D737CQ46677501-BE675EF8-C372-4C45-A91F-470E7D415C1DQ56896528-3B2E2771-31CA-43C8-A873-70284A6271C7Q57079509-CA10DDD0-D214-4BAE-A71C-AAC4E1D8F47C
P2860
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
The therapeutic effects of an ...... P571) in rheumatoid arthritis.
@en
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody
@nl
type
label
The therapeutic effects of an ...... P571) in rheumatoid arthritis.
@en
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody
@nl
prefLabel
The therapeutic effects of an ...... P571) in rheumatoid arthritis.
@en
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody
@nl
P2093
P356
P1476
The therapeutic effects of an ...... P571) in rheumatoid arthritis.
@en
P2093
P304
P356
10.1093/RHEUMATOLOGY/34.4.334
P577
1995-04-01T00:00:00Z